COMP <GO>
AXGN vs ABBV // FORWARD P/E MULTIPLE
Axogen Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AXGN 6
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: AXGN
LAST: $49.37 (-0.52%) • MKT CAP: $2.96B
forward-pe
18.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 70.20% | +4.10 | AXGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.60% | 29.00% | -31.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 3.47% | -3.57 | ABBV | /fcf-yield <GO> |
| Operating Margin | -3.50% | 24.60% | -28.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 6.90% | -13.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 8.60% | +11.60 | AXGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.64 | 5.33 | +13.31 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | AXGN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.9 | 72.8 | +1.15 | AXGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.0x | 113.1x | -95.10 | AXGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $513.86B | -$510.90B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | ABBV REV | AXGN GROSS % | ABBV GROSS % | AXGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $61.16B | 74.3% | 70.2% | -$2.9M | $17.82B |
| FY 2024 | $187.3M | $56.33B | 75.8% | 70.0% | $1.4M | $17.83B |
| FY 2023 | $159.0M | $54.32B | 44.0% | 44.0% | -$12.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
ABBV // BETA 1.15